Janchor Partners
Janchor Partners Ltd. is a hedge fund management firm established in 2009 that focuses on long-term industrialist investments. The firm partners with companies that exhibit superior business models and favorable growth prospects, particularly within Asian markets. Janchor Partners aims to enhance long-term corporate value by acting as a thoughtful partner to its investee companies, fostering deep relationships built on insight and trust. This collaborative approach is designed to create sustainable value and positive impacts over time. The firm's investment strategy is supported by a network of high-quality global institutional investors, including family offices, university endowments, foundations, and pension funds, who commit their capital for extended periods. Through this model, Janchor Partners seeks to achieve holistic outcomes that benefit all stakeholders involved.
FPL Technologies Pvt. Ltd., founded in 2019 and headquartered in Mumbai, India, focuses on providing innovative financial solutions for a digitally savvy younger population. The company has developed a proprietary technology platform that aims to enhance the credit card experience, capitalizing on the growing demand for consumption credit in India. With the recent surge in digital payment adoption, FPL recognizes the need for a more user-friendly approach to credit management. Their flagship product, the One Score app, launched to help users check and understand their credit scores, offers a secure and straightforward way to manage credit behavior. By integrating an intuitive mobile application with their credit card services, FPL Technologies seeks to meet the evolving needs of millennials and improve their overall financial literacy and credit experience.
Abbisko Therapeutics Co. Ltd. discovers, develop, and manufactures immuno-oncology therapies. It offers ABSK011 and ABSK021, which are molecule inhibitors for treating hepatocellular carcinoma; and CSF1R for the treatment of solid tumors. The company also develops therapeutics for the treatment of cancer, tumor, and diabetes, metabolic diseases, liver diseases, viral infections and CNS diseases. The company was founded in 2016 and is based in is based in Shanghai, China.
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company is advancing a pipeline of small molecule drug candidates targeting lung cancer, breast cancer, and gout. Notably, it is developing D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor, and is exploring combinations of its drugs with other immuno-oncology therapies, such as PD-1 antibodies, for various cancer indications. Co-founded by Dr. Yaolin Wang and a team of scientists with prior experience at major pharmaceutical companies like Merck and Schering-Plough, InventisBio aims to leverage their expertise in oncology and metabolic diseases to bring effective treatments to market.
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. The company was founded in 2017 and is headquartered in Shanghai, China.
RemeGen Co., Ltd. is a biopharmaceutical company based in Yantai, China, that focuses on the discovery, development, and commercialization of biologics aimed at addressing unmet medical needs in autoimmune, oncology, and ophthalmic diseases. Established in 2008, RemeGen specializes in innovative biologics, including monoclonal antibodies and antibody-drug conjugates. Its key products under development include Telitacicept, which targets autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, and Disitamab Vedotin for various cancers. The company is also advancing other candidates like RC28 and RC88 for retinal conditions, alongside several pre-clinical products aimed at treating solid tumors. RemeGen operates primarily in China but also maintains laboratories and offices in Beijing and California, emphasizing its commitment to fulfilling the medical needs of patients with life-threatening conditions.
Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.
Alphamab Oncology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the research, development, manufacturing, and commercialization of biologics for cancer treatment. The company has established a diverse product pipeline that includes several innovative therapeutics, such as KN046, a bispecific monoclonal antibody targeting PD-L1 and CTLA-4, currently in Phase II trials, and KN026, a next-generation anti-HER2 bispecific antibody also in Phase II. Additionally, the pipeline features KN019, a CTLA-4-based immunosuppressant fusion protein with potential applications in autoimmune diseases and oncology-related immune disorders, and KN035, an injectable PD-L1 inhibitor undergoing pivotal Phase II and III trials for various cancers. Founded in 2008, Alphamab Oncology utilizes proprietary platforms in bispecifics and protein engineering to address unmet medical needs globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.